TY - JOUR
T1 - Circulatory-cell-mediated nanotherapeutic approaches in disease targeting
AU - Burnouf, Thierry
AU - Burnouf, Pierre Alain
AU - Wu, Yu Wen
AU - Chuang, Er Yuan
AU - Lu, Long Sheng
AU - Goubran, Hadi
N1 - Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Circulating blood cells, and cell-derived microvesicles, are emerging as pragmatic delivery systems that can smartly complement the already existing nanotherapeutic platforms evaluated to treat or diagnose diseases. The valuable distinctive features of circulatory cells over synthetic nanocarriers encompass their biological origin which confers immune transparence, known biodegradability, high drug loading, relatively long half-life and a targeting capacity associated with their physiological surface functionality. Absence of nuclei in red blood cells and platelets provides further rationale for their use as cargo vehicles for nucleotoxic agents. Ongoing developments in cell-based and cell-inspired nanotherapies can move drug delivery into reachable frontiers and exhibit high potentiality for translatability into clinical use.
AB - Circulating blood cells, and cell-derived microvesicles, are emerging as pragmatic delivery systems that can smartly complement the already existing nanotherapeutic platforms evaluated to treat or diagnose diseases. The valuable distinctive features of circulatory cells over synthetic nanocarriers encompass their biological origin which confers immune transparence, known biodegradability, high drug loading, relatively long half-life and a targeting capacity associated with their physiological surface functionality. Absence of nuclei in red blood cells and platelets provides further rationale for their use as cargo vehicles for nucleotoxic agents. Ongoing developments in cell-based and cell-inspired nanotherapies can move drug delivery into reachable frontiers and exhibit high potentiality for translatability into clinical use.
UR - http://www.scopus.com/inward/record.url?scp=85029686136&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029686136&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2017.08.012
DO - 10.1016/j.drudis.2017.08.012
M3 - Short survey
AN - SCOPUS:85029686136
SN - 1359-6446
VL - 23
SP - 934
EP - 943
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 5
ER -